Neha Mehta-Shah
@NehaMehtaShahMD
Followers
465
Following
621
Statuses
165
Lymphoma doctor, clinical researcher, associate program director; Associate Professor at Wash U in St. Louis. Views and opinions are my own.
Joined December 2017
Thanks so much to @OncLive and @MedNewsWeek for organizing this! It was such a pleasure to take part with the one and only Kerry Savage!
Join us for Decoding T-Cell Lymphomas: An Approach to Diagnosis & Treatment a special @MedNewsWeek episode with @WomenInLymphoma! #Lymphoma #WomenInMedicine @NehaMehtaShahMD Featuring Kerry J. Savage, MSc, MD & Neha Mehta-Shah, MD, MSCI Register now:
0
3
5
RT @BloodJournal: The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy…
0
26
0
Congrats to our 2nd + 3rd year fellows who presented their original work at our annual research symposium! Always amazing to see them and their projects grow. Kudos to them, their mentors and our leadership for fostering creativity and innovation!
0
4
24
@Ferraro_lab @WashUDeptMed Congratulations Francesca, Michael and all the awardees and their labs!
0
0
2
Exciting to see this collaboration between Lauren Shea (@ UAB, former @WashUHemOncFell ) and I in print! Thanks @BloodJournal for the opportunity!
#Hematology Peripheral T-cell #lymphoma: are all patients high risk? @BloodJournal @ASH_hematology #lymsm
0
1
8
@tarsheen2 @poh_christina @CwynKate I have to admit I have no experience with this myself. When I had reviewed the literature with regards to another patient, it was unclear if those case reports truly had LGL in the CSF. This would be exceedingly uncommon.
1
0
1
RT @BloodCancerTalk: Our first post-#ASH24 episode just dropped! Lymphoma and CLL highlights with @dgermain21! We discuss: TRIANGLE ENRICH…
0
7
0
0
0
1
RT @WashUHemOncFell: Here Emily presents her work about the underutilization of hereditary cancer risk assessment in clinics serving predom…
0
2
0
RT @WashUHemOncFell: @giuliapetr0ne @ASH_hematology Next, third-year fellow @INizMD presenting results from a phase I clinical trial in pat…
0
2
0
RT @WashUHemOncFell: @giuliapetr0ne @ASH_hematology @INizMD @NehaMehtaShahMD @SitemanCenter @WashUOncology First-year #HFFTP fellow Amir Ma…
0
1
0
RT @WUSTLphs: Congrats to Graham Colditz, MD, DrPH., chief of PHS, on receiving the Brinker Award for Scientific Distinction in Population…
0
2
0
🤩 So proud of @INizMD who elegantly presented our study of acala+durvalumab in primary CNS lymphoma. - acalabrutinib penetrates the CNS - study is enrolling at @SitemanCenter and Ohio State @WashUHemOncFell
Woot woot! @INizMD @NehaMehtaShahMD presenting their IIS examining acalabrutinib + durvalumab in relapsed CNS lymphoma. @SitemanCenter @WashUOncology @WashUHemOncFell
0
4
33
RT @WashUHematology: Congrats to Dr. Amir Mahmoud our Hematology-Focused Fellow (HFFTP) on his poster presentation of thrombotic thrombocyt…
0
3
0
RT @dgermain21: Very pleased to be here in SD for #ASH24! Lots of exciting stuff in lymphoma from @WashUOncology, which I'll be highlightin…
0
1
0
So excited to welcome these stellar young doctors to the WashU Heme/onc family!
We are excited to welcome our 2025 @WashUHemOncFell Fellowship Class! More details➡ @WashUDeptMed @SitemanCenter @BarnesJewish @washumedicine @SanaSaifUrRehm @NehaMehtaShahMD @CyclingDoctor @WashUHematology @WashUOncology @mpndoc @abbyWUim
#MedEd
0
0
8
Excited to see @INizMD present our work to study acalabruitinib+durvalumab in primary CNS lymphoma! @WashUHemOncFell @WashUOncology
Acala+durva R/R PCNSL @NehaMehtaShahMD #ASH24: - 13 pts, 62% non-GC - 69% G3 TEAEs: PNA, cytopenias; 2 G3 irAEs (diarrhea, LFTs) - ORR 40% (CR 40%), 3 pts remain in CR - 63% had detectable CSF acalabrutinib, only 25% durva Acala has CSF penetration at 100-200 mg bid dose! #lymsm
0
1
21